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S306 Poster Session IIup time of 6.5 months, one patient died of disease relapse (ALL),
Two patients died of acute GVHD and 7 patients are alive without
evidence of leukemia. CPX-351 followed by RIC SCT is feasible,
and further dose escalation and schedule adjustment to define
MTD is ongoing. Remission status is not a prerequisite for a success-
ful outcome in selected patients.418
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We evaluated the impact of busulfan dose-intensity in patients un-
dergoing RTC AHCT in a multicenter retrospective study of 112
consecutive patients. Seventy-five patients were conditioned with
busulfan (0.8 mg/kg/dose IV x 8 doses [6.4mg/kg total dose]), fludar-
abine (30mg/m2/day, days -7 to -3), and 6mg/kg of ATG (L-FBA
group), while 37 patients received a more-intense RTC with busul-
fan (130mg/m2/day IV, days -6 to -3 [12.8mg/kg total dose]), fludar-
abine (40mg/m2/day, days -6 to -3), and 6mg/kg of ATG (H-FBA
group). At baseline (see Table 1.) the L-FBA and H-FBA groups
were matched for median age (58yr vs. 55yr; p5 0.3), unrelated do-
nor allografts (88% vs. 75%; p 5 0.1), and HLA-mismatched allo-
grafts (22% vs. 21%; p 5 0.9). More patients in L-FBA group had
high-risk disease (88% vs. 75%; p 5 0.01), higher median HCT-
CI (2 vs. 1; p 5 0.01) and better KPS (90 vs. 80; p 5 0.001).
Table 1. Baseline Characteristics of Patients Undergoing RTC
with FBA
L-FBA [N575] H-FAB [N537] p-ValueAge (median) 58 years 55 years 0.3
Unrelated Donors 66 (88%) 28 (75%) 0.1
High-risk Disease* 66 (88%) 25 (67%) 0.01
Diagnosis
AML/ALL 28% 43% 0.1
MDS 12% 21% 0.18
NHL/Hogkin’s Lymphoma 24% 21% 0.77
CLL/CML 34% 8% 0.002
Others 1.3% 5.4% 0.2
KPS (median) 90 80 0.001
HCT-CI (median) 2 1 0.01
HLA-mismatched transplants 17 (22%) 8 (21%) 0.9
Follow-up (surviving pts;
median)404 days 378 days 0.2*High-risk per standard CIBMTR criteria. HCT-CI, Hematopoietic cell
transplantation comorbidity index; KPS, Karnofsky performance score.
GVHD prophylaxis consisted of micro-dose methotrexate/ calci-
neurin inhibitor combination. There were no graft rejections. Me-
dian time to neutrophil (16days vs. 17days; p 5 0.03) and platelet
engraftment (14days vs. 16days; p 5 0.0001) was significantly faster
in H-FBA group. Compared to patients receiving H-FBA, those re-
ceiving L-FBA had fewer bacterial infections (56% vs. 32%; p-value
5 0.01), similar CMV reactivations (p5 0.6) and more EBV reacti-
vations (0% vs. 16%; p 5 0.001). For L-FBA and H-FBA groups
rates of grade II-IV acute GVHD (41% vs. 47%; p-value 5 0.68),
and chronic GVHD (35% vs. 46%; p-value5 0.21) were not signif-
icantly different. In similar order at 1-year the cumulative-incidence
of non-relapse mortality (NRM) (11% vs. 22%; p-value 5 0.2) and
relapse rates (37% vs. 40%; p5 0.8) were not significantly different.
The median follow-up of surviving patients is 14 months. Patients in
L-FBA and H-FBA groups had similar 1-year overall survival (61%
vs. 50% p5 0.1) and progression free survival (51% vs. 36% p-value
5 0.3). Our data suggest that merits of higher busulfan dose-inten-
sity in the context of FBA-based RTC may be offset by slightlyincreased early morbidity and NRM, suggesting prospective trials
are warranted.
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THE NUMBER OF CD34+ CELLS IN PERIPHERAL BLOOD PRE LEUKAPHE-
RESIS OF ALLOGENEIC STEM CELL DONORS IS RELATED TO DONOR
DEMOGRAPHIC AND HEMATOLOGIC FACTORS ON THE DAY OF COLLEC-
TION. RESULTS OF A SINGLE CENTER STEM CELL COLLECTION
VALIDATION STUDY
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Introduction: Leukapheresis has become the preferred tool of stem
cell collection for allogeneic transplants. CD34 cell count per ml in
peripheral blood on the day of collection can be used to estimate col-
lection yield. CD34 counts show variability related to donor specific
factors. We have identified in this study predictive factors influenc-
ing CD34 cell count and collection yield in a homogenous cohort of
donors.
Methods: 269 collections were performed in 217 consecutive alloge-
neic stem cell transplant donors in the pheresis unit of Maisonneuve
Rosemont Hospital between 2006 and 2009. Median age was 50
years (22-76). 99 (46%) were female. G-CSF was used at a dose of
5mg/kg BID for 4 days. Collections were initiated at a level of 10
CD34 cells/ml on day 5 using a Cobe Spectra pheresis device.
Results:Median blood volume cycled was 15.9 liters (5-20). 174 do-
nors (80%) required one collection to achieve a graft of 5x106/kg, 43
required additional collections. Median CD34 count/ml was 71 (4.5-
378.5). Male had a higher CD34 count/ml on all days of collection as
female donors (95 versus 73 CD34/ml, p5 0.001). Women and men
above the age of 55 had lower CD34 counts/ml as compared to youn-
ger donors (women: 94 versus 74, p5 0.022; men: 113 versus 83, p5
0.013). More female than male donors required multiple collections
to achieve a satisfactory graft (27 versus 14%, p\0.01). There were
statistically significant positive correlations between total leucocyte
(lc), mononuclear cell (MNC), platelet (plt) and CD34 counts/ml
measured in the peripheral blood. No correlation between hemoglo-
bin and CD34 count was noted. A median of 4.8x108 CD34 + cells
were collected per graft (0.2-19.5). A significant positive correlation
was noted between collection yield and pre collection total lc, MNC,
plt, CD34 /ml and total lc count in the graft. The median collection
efficiency (CE) for the whole cohort was 42%.We observed a signif-
icantly higher CE using a manual mode of collection as compared to
an automatic mode (46 vs 29%, p\ 0.001).
Conclusions: CD34 cell count pre collection is affected by donor
age and gender. A higher proportion of female donors require mul-
tiple collections. A number of haematological parameters are corre-
lated with an elevated CD34 count in peripheral blood on the day of
collection.These factors help determine donors at higher risk of a de-
creased yield of stem cell collection. A manual mode of collection
appears to lead to superior collection efficiency.420
THE ROLE OF AMD3100 AS A PREPARATIVE REGIMEN IN ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
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Since the development of allogeneic hematopoietic cell transplan-
tation (HCT),many advances have beenmade that allowHCT treat-
ment to be utilized in a wider range of patients. In the face of all these
developments, additional barriers to engraftment have emerged. In
addition to the immune barrier, non-immune related barriers are
thought to contribute to engraftment resistance. One physical bar-
rier of HCT engraftment is a need for space in the host hematopoi-
etic stem cell (HSC) niche. It has been suggested that donor cells
must home to specific areas in the bone marrow, engraft, and prolif-
erate in these spaces. If endogenous HSCs occupy the niche, it is hy-
pothesized that incoming donor cells will not be able to engraft.
AMD3100 is a small molecule antagonist of CXC chemokine re-
ceptor 4 (CXCR4) and functions to block CXCR4 and stromal
cell-derived factor-1 (SDF-1) interactions. This blockade results in
